tovaxin
Vaccineexperimental
Tcelna is an anti-T cell vaccine being studied in multiple sclerosis (MS). As of 2016 it is in phase II trials. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2002 (NCT00587691)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, desensitized
immunity, desensitized
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00595920 | Phase 2 | Nov 1, 2007 | Central Texas Neurology Consultants, Opexa Therapeutics |
| NCT00245622 | Phase 2 | May 1, 2006 | Central Texas Neurology Consultants, Opexa Therapeutics |
| NCT00587691 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2002 | Opexa Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Opexa Therapeutics | For profit | 3 | 3 | 1 | 2002 |
| Central Texas Neurology Consultants | Academic/Hospital | 2 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1